Achiko AG – Publication of the annual report and annual financial statements 2021 is due by June 26, 2022
ZURICH, Switzerland, June 20, 2022 (GLOBE NEWSWIRE) — ad-hoc andnotohyounment couldrknownanot to Art. 53LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and annual financial statements for the year 2021 on June 26, 2022 at the latest .
As a SIX-listed company, Achiko is required to publish its annual report, as well as annual financial statements, within four months of the balance sheet date. Due to the Covid-19 pandemic, new staff and training under difficult conditions following the measures taken by several countries required a great deal of management capacity. Consequently, the publication of the 2021 annual report, together with the annual financial statements and the audit report, will take place in June 2022.
Achiko filed an exemption request with SIX Exchange Regulation (SER) regarding the publication of the 2021 annual report and annual accounts. On April 28, 2022, SER granted Achiko the requested extension. Achiko filed a second extension request with SER regarding the publication of the 2021 Annual Report and Annual Financial Statements. On May 30, 2022, SER granted Achiko the second extension. Achiko filed a third extension request with SER regarding the publication of the 2021 Annual Report and Annual Financial Statements. On June 3, 2022, SER granted Achiko the third extension. On June 10, 2022, Achiko filed a fourth extension request with SER regarding the publication of the 2021 annual report and annual financial statements. On June 10, SER granted Achiko the fourth extension. On June 20, 2022, Achiko filed a fifth extension request with SER regarding the publication of the 2021 annual report and annual financial statements. On June 20, SER granted Achiko the fifth extension.
The delay is based on previously announced elements, including the continuity of operations in the second half of the fiscal year due to the Covid-19 pandemic and the higher than expected manual administrative workload, in particular with regard to documentation. auditory reconciliation. Additionally, the Company’s CEO contracted Covid-19 during calendar week 23/2022, limiting his ability to quickly compile relevant accounting documentation and interact with others in physical meetings.
As required by SER, Achiko hereby reprints par. I of the respective decision of the SER:
“Achiko’s (issuer) waiver request dated June 20, 2022, requesting a fifth extension of the deadline for publishing its 2021 annual report and filing this report with SIX Exchange Regulation AG until June 26, 2022 , is granted with the following reservation (lit. a) and under the following conditions (lit. b):
SIX Exchange Regulation AG reserves the right to suspend trading in the issuer’s registered shares if its annual report 2021 is not published in accordance with the provisions on ad hoc publicity (Art. 53 of the Listing Regulations [LR] in connection with the directive on event advertising [DAH]) and filed with SIX Exchange Regulation AG by Sunday, June 26, 2022, 11:59 p.m. CET, at the latest
Achiko is required to publish a notice in accordance with the provisions on event advertising (art. 53 LR in relation to the DAH) concerning this decision until Monday, June 20, 2022, 11:59 p.m. CET, at the latest. The notice must contain:
˗ the reproduction without modification of the wording of s. I. of this decision, placed in first place;
˗ the reasons for the Issuer’s request for a fifth extension of the deadline for publishing its 2021 annual report and for filing this report with SIX Exchange Regulation AG.”
The date of the next annual general meeting will be announced in due course, once the Company has published its annual report and annual financial statements for the year 2021.
ON ACHIKO Ag
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) develops disruptive diagnostic solutions that put people first. The company’s flagship product is a fast and reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and an application for CE mark approval in Europe will be submitted in 2022.
Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameXMT and complementary health apps through its digital mobile health technology division, Teman SehatMT. AptameX DNA aptamer assays can be rapidly chemically synthesized, are cost effective and have broad potential for the diagnosis of several diseases. Leveraging AptameX and Teman Sehat, Achiko aims to provide rapid, accurate and affordable diagnostic tests for a range of pathogenic diseases and therapeutic indications in the rapidly evolving field of healthcare diagnostics.
Based in Zurich, Achiko has offices in Jakarta and staff worldwide.
E: [email protected]
SwissIand & gheybAl
Farner Consulting Ltd.
E: [email protected]
Such. : +41 44 266 67 67
Jhis communvsationot expressthere Where Imexplicitly vsohntaIns definitelyInot FWhereward-lookIng statements vsohcerning Achickoh AG oneD thiss Company. Juiceh statisticaleis lyings invOLVe somenot knotohwnot anotD UNkNopewnot risks, underyouainties, anotelser Factors, wHellovsh couldD cause the newsI results, FInotcohnitiohn, byFWheremance, or achieclothings ohF Achickoh AG be materialIand Ifferent Fof any Fyouyouure results, perFormance or accomplishements expressed or impliedD by such FWhereward-lohok Inotg-stateents. Achico AG provides this commUnitedvsatiohn like oF this date and Dwheres not youunderyouake at youpDate anotthere FWhereward-Ioknotg statisticalecomments containeD here as a results ohF notw inFformatIon, future evenotts or ohthewis.